Aradigm Corp. announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis. The randomized, double-blind, placebo-controlled trial will be conducted in Australia and New Zealand. Following a 14-day screening period, the patients will be treated once a day for 28 days with either the active drug, or placebo, followed by a 28-day off-treatment period. This on-off sequence will be repeated three times. The primary endpoint is defined as the mean change in Pseudomonas aeruginosa density in sputum (colony forming units--CFU-per gram) from baseline to day 28 of the active treatment group versus placebo. Safety and tolerability assessments of the treatment versus placebo group will be performed and secondary efficacy endpoints will include long-term microbiological responses, time to an exacerbation, severity of exacerbations, length of time to resolve exacerbations, and changes in spirometry and in quality-of-life measurements. The study will explore whether the novel formulation ARD-3150, which has a different drug release profile than ARD-3100 (the formulation being studied under a U.S. IND in a separate 1-month dosing Phase 2b trial in a similar patient population), may have additional therapeutic benefits. The 6-month study will also generate valuable data on the long-term impact of once-daily inhaled ciprofloxacin in patients with severe bronchiectasis.

Aradigm Corp. expected to Report Fiscal Year 2009 Results on March 22, 2010. This event was calculated by Capital IQ (Created on November 6, 2009).

Aradigm Corp. announced unaudited financial results for the third quarter and nine months ended September 30, 2009. Revenue for the third quarter of 2009 was $4.9 million, compared to revenue of $0.2 million for the third quarter of 2008. The company's net loss for the third quarter of 2009 was $0.6 million, or $0.01 per share, compared to a net loss of $4.6 million, or $0.08 per share, for the third quarter of 2008. Loss from operations was $504,000 against $4.6 million a year ago. For the nine months, the company reported revenues of $4.9 million against $251,000 a year ago. The company's net loss was $10.4 million, or $0.12 per share, compared to a net loss of $17.3 million, or $0.32 per share a year ago. Loss from operations was $10.2 million against $17.69 million a year ago. For the quarter, the company reported restructuring and asset impairment charges of $1.6 million against $19,000 a year ago.